Business Context and Reporting Period
Company: Armata Pharmaceuticals, Inc. (ARMP)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Armata is a late clinical-stage biotechnology company developing pathogen-specific bacteriophage therapeutics to treat antibiotic-resistant bacterial infections. The company focuses on two primary candidates: AP-PA02 (targeting Pseudomonas aeruginosa in chronic pulmonary infections) and AP-SA02 (targeting Staphylococcus aureus bacteremia). As of December 31, 2025, the company had 61 full-time employees and operates a cGMP manufacturing facility in Los Angeles, California.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Grant and Award Revenue | $4.9 million | $5.2 million |
| Total Operating Expenses | $41.5 million | $47.6 million |
| Net Loss | $(173.8) million | $(18.9) million |
| Cash and Cash Equivalents (Dec 31, 2025) | $8.7 million | $9.3 million |
| Accumulated Deficit (Dec 31, 2025) | $(501.5) million | $(327.7) million |
| Outstanding Debt (Principal) | $85.0 million | $60.0 million |
| Accrued Interest on Debt | $18.1 million | N/A |
Note: The 2025 Net Loss includes a non-cash loss of $121.0 million related to the change in fair value of a Convertible Loan.
Material Changes vs. Prior Period
- Net Loss Expansion: Net loss increased significantly from $18.9 million in 2024 to $173.8 million in 2025. This was primarily driven by a $121.0 million non-cash loss due to the change in fair value of the Convertible Loan, compared to a $31.4 million gain in the prior year.
- Operating Expenses: Total operating expenses decreased by 12.8% to $41.5 million. Research and Development (R&D) expenses dropped 31.1% to $23.7 million, largely due to the winding down of clinical trial activities for AP-PA02 and AP-SA02.
- Impairment Charge: The company recognized a $5.4 million impairment expense in 2025 related to office and R&D space in Marina del Rey, California, due to delays in subleasing the vacated space. No such charge existed in 2024.
- Debt Obligations: The company secured additional term debt in 2025, including a $15.0 million loan in August and a $10.0 million loan in March, increasing total principal debt to $85.0 million.
Guidance, Outlook, and Risks
Clinical Progress and Outlook
- AP-SA02 (S. aureus Bacteremia): The FDA confirmed that Phase 2a data supports advancement to Phase 3. The company received Qualified Infectious Disease Product (QIDP) designation in February 2026, making it eligible for Fast Track status and potential market exclusivity extensions. A Phase 3 superiority study is anticipated to initiate in the second half of 2026.
- AP-PA02 (P. aeruginosa): Completed Phase 2 studies in Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis (NCFB) showed durable reduction of bacterial load. Future Phase 3 development is contingent on securing sufficient funding.
- Manufacturing: The Los Angeles cGMP facility was formally commissioned in November 2025, enabling full-scale production for clinical trials and potential commercialization.
Liquidity and Going Concern
The company has stated that its existing cash of $8.7 million is insufficient to fund operations for the next 12 months. This raises substantial doubt about its ability to continue as a going concern. Management plans to raise additional capital through equity offerings, debt financings, or strategic collaborations. Failure to secure funding could result in curtailment of operations or bankruptcy.
Key Risks
- Capital Requirements: Heavy reliance on external financing; inability to raise funds could halt development.
- Convertible Loan Volatility: The fair value of the Convertible Loan is highly sensitive to stock price fluctuations, causing significant volatility in reported net income/loss.
- Regulatory Uncertainty: No bacteriophage products have been approved in the U.S.; regulatory pathways are novel and complex.
- Concentration of Ownership: Innoviva, Inc. owns approximately 68.8% of outstanding shares, exerting significant control over corporate governance.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the "substantial doubt" going concern warning and only $8.7 million in cash.
- Debt Covenants: Review the terms of the $85 million in term debt and the $30 million Convertible Loan, specifically regarding maturity dates (June 2027 and January 2029) and interest rates (14% for term debt).
- Phase 3 Funding: Confirm the specific funding requirements and timeline for initiating the AP-SA02 Phase 3 trial scheduled for late 2026.
- Convertible Loan Fair Value: Understand the impact of stock price volatility on the company's reported earnings, as the Convertible Loan is marked-to-market.
- Grant Revenue Sustainability: Assess the remaining value and recognition timeline of the $26.2 million MTEC (DoD) award and the $5.0 million CFF award.